Introduction
GXNPC1 is a novel autologous adipose-derived stem cell therapy for treating chronic stroke (first-in-class). In pre-clinical data, GXNPC1 has demonstrated that it can increase the expression of homing effect, anti-inflammation and angiogenesis. In simulating human ischemic stroke, the animal model showed significant improvement in a variety of behavior tests, including beam walking, locomotor activity, and rotarod analysis.
According to the data of GXNPC1 phase I, the outcomes demonstrated that there is no safety issue through 6 months observation. Moreover, all subjects with chronic stroke got significantly improved after GXNPC1 treatment. Currently, GXNPC1 is ongoing in clinical trial phase II (NCT04088149).
Features / strengths
．Advanced technology (first-in-class)
．Leading stem cell therapy in brain stroke
．Intracerebroventricular (ICV) injection
．The outcomes of phase I have been published (J Tissue Eng Regen Med. 2022;16(1):3-13. doi:10.1002/term.3256)
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Administration
Intracerebroventricular injection
Product Status:
Phase II (NCT04088149)
